LEADS BIOLABS-B (09887): LBL-034 Clinical Study Selected as First Oral Presentation on Opening Day of 67th ASH Annual Meeting

Stock News

Nov 04

LEADS BIOLABS-B (09887) announced that five research abstracts have been selected for presentation at the 67th Annual Meeting of the American Society of Hematology (ASH). The company is pleased to provide further details on its investigational drugs, LBL-034 and LBL-076, with multiple research abstracts accepted by the conference. Notably, one LBL-034 clinical study has been chosen as the first oral presentation on the opening day, showcasing the latest efficacy and safety data of LBL-034 in patients with relapsed/refractory multiple myeloma.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1101815562"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1101815562\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1101815562?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 06:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101815562","market":"sg","top_or_hot":-1,"title":"LEADS BIOLABS-B (09887): LBL-034 Clinical Study Selected as First Oral Presentation on Opening Day of 67th ASH Annual Meeting","media":"Stock News","content":"<p>LEADS BIOLABS-B (09887) announced that five research abstracts have been selected for presentation at the 67th Annual Meeting of the American Society of Hematology (ASH). The company is pleased to provide further details on its investigational drugs, LBL-034 and LBL-076, with multiple research abstracts accepted by the conference. Notably, one LBL-034 clinical study has been chosen as the first oral presentation on the opening day, showcasing the latest efficacy and safety data of LBL-034 in patients with relapsed/refractory multiple myeloma.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LEADS BIOLABS-B (09887): LBL-034 Clinical Study Selected as First Oral Presentation on Opening Day of 67th ASH Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLEADS BIOLABS-B (09887): LBL-034 Clinical Study Selected as First Oral Presentation on Opening Day of 67th ASH Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-04 06:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LEADS BIOLABS-B (09887) announced that five research abstracts have been selected for presentation at the 67th Annual Meeting of the American Society of Hematology (ASH). The company is pleased to provide further details on its investigational drugs, LBL-034 and LBL-076, with multiple research abstracts accepted by the conference. Notably, one LBL-034 clinical study has been chosen as the first oral presentation on the opening day, showcasing the latest efficacy and safety data of LBL-034 in patients with relapsed/refractory multiple myeloma.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2463526074.USD","symbol_name":"NORDEA 1 - GLOBAL CLIMATE ENGAGEMENT \"BP\" (USD) ACC","start_time":0,"source_url":"","article_id":"1101815562","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101815562","pubTimestamp":1762209616,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"LEADS BIOLABS-B (09887) announced that five research abstracts have been selected for presentation at the 67th Annual Meeting of the American Society of Hematology (ASH). The company is pleased to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2463526074.USD":"NORDEA 1 - GLOBAL CLIMATE ENGAGEMENT \"BP\" (USD) ACC","ASH":"Ashland","BK1161":"生物科技","BK4109":"特种化学制品","09887":"维立志博-B"},"translate_title":"LEADS BIOLABS-B(09887)：LBL-034临床研究被选为第67届ASH年会开幕当天的首次口头报告","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09887":1,"ASH":1},"content_text":"LEADS BIOLABS-B (09887) announced that five research abstracts have been selected for presentation at the 67th Annual Meeting of the American Society of Hematology (ASH). The company is pleased to provide further details on its investigational drugs, LBL-034 and LBL-076, with multiple research abstracts accepted by the conference. Notably, one LBL-034 clinical study has been chosen as the first oral presentation on the opening day, showcasing the latest efficacy and safety data of LBL-034 in patients with relapsed/refractory multiple myeloma.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}